231 related articles for article (PubMed ID: 29150788)
21. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.
Franceschini N; Gaeta R; Krimpenfort P; Briaire-de Bruijn I; Kruisselbrink AB; Szuhai K; Palubeckaitė I; Cleton-Jansen AM; Bovée JVMG
Lab Invest; 2022 Apr; 102(4):391-400. PubMed ID: 34921235
[TBL] [Abstract][Full Text] [Related]
22. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
[TBL] [Abstract][Full Text] [Related]
23. Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report.
Camacho-Urkaray E; Santos-Juanes J; Gutiérrez-Corres FB; García B; Quirós LM; Guerra-Merino I; Aguirre JJ; Fernández-Vega I
Cell Oncol (Dordr); 2018 Apr; 41(2):213-221. PubMed ID: 29218546
[TBL] [Abstract][Full Text] [Related]
24. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.
Witkiewicz AK; Knudsen KE; Dicker AP; Knudsen ES
Cell Cycle; 2011 Aug; 10(15):2497-503. PubMed ID: 21775818
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
26. Lack of germ-line mutations of CDK4, p16(INK4A), and p15(INK4B) in families with glioma.
Gao L; Liu L; van Meyel D; Cairncross G; Forsyth P; Kimmel D; Jenkins RB; Lassam NJ; Hogg D
Clin Cancer Res; 1997 Jun; 3(6):977-81. PubMed ID: 9815774
[TBL] [Abstract][Full Text] [Related]
27. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.
Zhu H; Acquaviva J; Ramachandran P; Boskovitz A; Woolfenden S; Pfannl R; Bronson RT; Chen JW; Weissleder R; Housman DE; Charest A
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2712-6. PubMed ID: 19196966
[TBL] [Abstract][Full Text] [Related]
29. A heat shock protein 90 inhibitor reduces oncoprotein expression and induces cell death in heterogeneous glioblastoma cells with EGFR, PDGFRA, CDK4, and NF1 aberrations.
Ho KT; Chen PF; Chuang JY; Gean PW; Hsueh YS
Life Sci; 2022 Jan; 288():120176. PubMed ID: 34848192
[TBL] [Abstract][Full Text] [Related]
30. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme.
Qiu S; Huang D; Yin D; Li F; Li X; Kung HF; Peng Y
Biochim Biophys Acta; 2013 Oct; 1832(10):1697-707. PubMed ID: 23707559
[TBL] [Abstract][Full Text] [Related]
31. Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.
Schrage YM; Lam S; Jochemsen AG; Cleton-Jansen AM; Taminiau AH; Hogendoorn PC; Bovée JV
J Cell Mol Med; 2009 Sep; 13(9A):2843-52. PubMed ID: 18624751
[TBL] [Abstract][Full Text] [Related]
32. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells.
Sandhu C; Peehl DM; Slingerland J
Cancer Res; 2000 May; 60(10):2616-22. PubMed ID: 10825132
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas.
Burns KL; Ueki K; Jhung SL; Koh J; Louis DN
J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204
[TBL] [Abstract][Full Text] [Related]
34. Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.
Olmez I; Zhang Y; Manigat L; Benamar M; Brenneman B; Nakano I; Godlewski J; Bronisz A; Lee J; Abbas T; Abounader R; Purow B
Cancer Res; 2018 Aug; 78(15):4360-4369. PubMed ID: 29844123
[TBL] [Abstract][Full Text] [Related]
35. p16(INK4a) Peptide mimetics identified via virtual screening.
Klein MA; Mayo KH; Kratzke RA
Bioorg Med Chem Lett; 2010 Jan; 20(1):403-5. PubMed ID: 19914831
[TBL] [Abstract][Full Text] [Related]
36. Tumor suppressor p16INK4A is necessary for survival of cervical carcinoma cell lines.
McLaughlin-Drubin ME; Park D; Munger K
Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16175-80. PubMed ID: 24046371
[TBL] [Abstract][Full Text] [Related]
37. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.
Peurala E; Koivunen P; Haapasaari KM; Bloigu R; Jukkola-Vuorinen A
Breast Cancer Res; 2013 Jan; 15(1):R5. PubMed ID: 23336272
[TBL] [Abstract][Full Text] [Related]
38. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
39. Differential expression of PDGFRB and EGFR in microvascular proliferation in glioblastoma.
Xu G; Li JY
Tumour Biol; 2016 Aug; 37(8):10577-86. PubMed ID: 26857280
[TBL] [Abstract][Full Text] [Related]
40. Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.
Bronner SM; Merrick KA; Murray J; Salphati L; Moffat JG; Pang J; Sneeringer CJ; Dompe N; Cyr P; Purkey H; Boenig GL; Li J; Kolesnikov A; Larouche-Gauthier R; Lai KW; Shen X; Aubert-Nicol S; Chen YC; Cheong J; Crawford JJ; Hafner M; Haghshenas P; Jakalian A; Leclerc JP; Lim NK; O'Brien T; Plise EG; Shalan H; Sturino C; Wai J; Xiao Y; Yin J; Zhao L; Gould S; Olivero A; Heffron TP
Bioorg Med Chem Lett; 2019 Aug; 29(16):2294-2301. PubMed ID: 31307887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
